Want to see SE:EGTX full AI Analyst Report?
Egetis Therapeutics AB (EGTX) AI Stock Analysis
Egetis Therapeutics AB
(Nasdaq OMX AB:EGTX)
The score is held down primarily by weak financial performance—substantial ongoing losses and significant cash burn—despite some revenue improvement and a recovering gross margin. Technicals are a relative positive with the price above major moving averages, but valuation remains challenging given the negative P/E and no dividend yield data.
Egetis Therapeutics AB (EGTX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 4.68B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.15M
- Price to Earnings (P/E)
- -10.0
- Beta (1Y)
- -0.29
- Revenue Growth
- 39.45%
- EPS Growth
- -1.02%
- Country
- Sweden
- Employees
- 56
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Egetis Therapeutics AB Business Overview & Revenue Model
Company Description
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug s...
Egetis Therapeutics AB Financial Statement Overview
Summary
Financials are dominated by heavy losses and large ongoing cash burn (negative operating cash flow and free cash flow around -300M TTM). Revenue has improved to 66.1M TTM and gross margin has recovered to ~14%, and leverage is moderate (debt-to-equity ~0.30), but deeply negative operating/net margins and negative ROE indicate the business remains far from sustainable profitability.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.10M | 62.40M | 46.10M | 57.60M | 22.50M | 38.24M |
| Gross Profit | 11.10M | 12.40M | 34.50M | -146.90M | -120.10M | -58.28M |
| EBITDA | -379.60M | -343.20M | -317.30M | -319.10M | -191.00M | -101.90M |
| Net Income | -405.50M | -342.50M | -343.60M | -326.90M | -189.50M | -104.73M |
Balance Sheet | ||||||
| Total Assets | 760.50M | 639.10M | 792.30M | 760.20M | 561.10M | 569.27M |
| Cash, Cash Equivalents and Short-Term Investments | 378.40M | 215.80M | 351.00M | 303.30M | 127.70M | 143.97M |
| Total Debt | 68.80M | 90.60M | 117.40M | 113.00M | 2.70M | 4.20M |
| Total Liabilities | 278.90M | 300.40M | 299.40M | 214.60M | 54.90M | 42.23M |
| Stockholders Equity | 481.50M | 338.70M | 492.80M | 545.60M | 506.20M | 527.04M |
Cash Flow | ||||||
| Free Cash Flow | -301.30M | -268.60M | -227.90M | -278.40M | -173.50M | -130.28M |
| Operating Cash Flow | -300.30M | -267.10M | -227.90M | -278.40M | -173.50M | -130.11M |
| Investing Cash Flow | -2.70M | -2.80M | -1.20M | -100.00K | -1.70M | -5.96M |
| Financing Cash Flow | 474.00M | 140.00M | 270.90M | 458.90M | 155.70M | -8.90M |
Egetis Therapeutics AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EGTX, the sentiment is Positive. The current price of 9.95 is above the 20-day moving average (MA) of 9.56, above the 50-day MA of 8.63, and above the 200-day MA of 6.47, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 62.38 is Neutral, neither overbought nor oversold. The STOCH value of 75.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EGTX.
Egetis Therapeutics AB Peers Comparison
Overall Rating
- SE:EGTX50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:EGTX | 50Neutral | SEK 4.68B | -9.96 | -120.49% | ― | 39.45% | -1.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:EGTX | Egetis Therapeutics AB | 10.06 | 3.75 | 59.43% |
Egetis Therapeutics AB Corporate Events
Egetis Therapeutics Launches First FDA-Approved EMCITATE Therapy for MCT8 Deficiency in U.S.
Egetis Therapeutics has launched EMCITATE in the United States for adults and pediatric patients with MCT8 deficiency, making available the first and only FDA-approved treatment for peripheral thyrotoxicosis associated with this rare, life-limiting g...
Egetis Therapeutics Sets Nomination Committee for 2027 AGM
Egetis Therapeutics AB has appointed the members of its Nomination Committee ahead of the 2027 Annual General Meeting scheduled for May 12, 2027. Representatives from Frazier Life Sciences, Cidro Förvaltning AB and Cetoros AB will serve on the C...
Egetis bolsters tiratricol case with largest RTH-beta cohort study
Egetis Therapeutics has highlighted new clinical evidence for its thyroid hormone analogue tiratricol, following publication in eBioMedicine of the largest retrospective cohort study to date in patients with resistance to thyroid hormone beta. The mu...
Egetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise
Egetis Therapeutics has reported changes in the composition of its share and vote structure for September following the exercise of employee stock options under its 2022–2026 and 2023–2026 programs. While the total number of shares and sh...
Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE
Egetis Therapeutics has received U.S. FDA approval for EMCITATE (tiratricol), the first and only treatment in the United States for peripheral thyrotoxicosis in adults and children with MCT8 deficiency, a severe and life-limiting X-linked thyroid hor...
Egetis to Present New Emcitate Data at Major European Endocrinology Meetings
Egetis Therapeutics will showcase new clinical data for Emcitate, its thyroid hormone analogue tiratricol for MCT8 deficiency, at two major endocrinology conferences in Europe this September. The data from the Triac Trial II and ReTRIACt studies will...
Egetis Steps Up Investor Outreach Ahead of Key FDA Decision
Egetis Therapeutics will showcase its progress to investors at two major New York healthcare conferences in September, where CEO Nicklas Westerholm is scheduled for fireside chats and one-on-one meetings, with sessions available via webcast. The inve...
Egetis Wins Japanese Orphan Status for Emcitate in Rare MCT8 Disorder
Egetis Therapeutics’ partner Fujimoto Pharmaceutical has secured orphan drug designation in Japan for Emcitate (tiratricol) in MCT8 deficiency, strengthening the product’s regulatory footing across major markets. The Japanese status bring...
Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
Egetis Therapeutics reported second-quarter 2026 net revenue of SEK 17.4 million from Emcitate sales in Europe, up 23% at constant exchange rates versus a year earlier, while posting a quarterly loss of SEK 108.9 million as it invests in U.S. launch...
Egetis sets Q2 2026 results date as Emcitate nears key FDA decision
Egetis Therapeutics will publish its second-quarter 2026 report on August 21 and host a same-day conference call offering a corporate and financial update, followed by a Q&A session, with participation available via webcast or teleconference and...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026